Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eIF4E inhibitor

- PMLiVE

ViiV’s Tivicay for HIV on course for EU approval

More positive news for GSK, Pfizer and Shionogi joint venture

- PMLiVE

GSK and Pfizer combine melanoma drugs in new trial

Will investigate effects of adding palbociclib to Mekinist

- PMLiVE

Pfizer extends optimisation campaign

Pharma company supports efforts to ensure public get best out of medicines

- PMLiVE

How Pfizer reclaimed its Twitter brand

Company explains how it took back its name on the social network

Pfizer finally acquires the @pfizer name on Twitter

Will streamline its existing @pfizer_news account

- PMLiVE

Scotland first in UK to back Pfizer’s Inlyta

SMC also recommends Astellas' Xtandi but not Pfizer's Bosulif

- PMLiVE

Pfizer slams UK drug pricing plan

BioIndustry Association 
also challenges revision to PPRS

- PMLiVE

Pfizer sales down but oncology shows promise

Toll of patent expiries continues

- PMLiVE

Pfizer calls for mHealth to be prioritised

Wants more action to support mobile health in developing countries' ageing populations

- PMLiVE

Xeljanz effective in psoriasis says Pfizer

Data backs extension of drug’s indications

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

- PMLiVE

Adobe CEO joins Pfizer board

Shantanu Narayen joins corporate governance and science and technology committees

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links